pyridazine has been researched along with Idiopathic Pulmonary Fibrosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allart, B; Borgonovi, M; Brys, R; Christophe, T; Clément-Lacroix, P; Coornaert, B; Duys, I; El Bkassiny, S; Heckmann, B; Houvenaghel, N; Jans, M; Jaunet, A; Joannesse, C; Mammoliti, O; Menet, C; Oste, L; Palisse, A; Sanière, L; Sonck, K; Wakselman, E | 1 |
1 other study(ies) available for pyridazine and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis.
Topics: Animals; CHO Cells; Cricetulus; Drug Design; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-8; Male; Mice; Pyridazines; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Tissue Distribution | 2021 |